Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL

Blinatumoab公司 CD19 癌症研究 免疫学 生物 医学 内科学 肿瘤科 抗体
作者
Yaqi Zhao,Ibrahim Taha Aldoss,Chunxu Qu,Jeremy Chase Crawford,Zhaohui Gu,Emma Kaitlynn Allen,Anthony Elston Zamora,Thomas Alexander,Jeremy Wang,Hiroaki Goto,Toshihiko Imamura,Koshi Akahane,Guido Marcucci,Anthony Selwyn Stein,Ravi Bhatia,Paul Glyndwr Thomas,Stephen J. Forman,Charles Grenfell Mullighan,Kathryn G. Roberts
出处
期刊:Blood [Elsevier BV]
卷期号:137 (4): 471-484 被引量:172
标识
DOI:10.1182/blood.2020006287
摘要

Blinatumomab, a bispecific antibody that directs CD3+ T cells to CD19+ tumor cells, shows variable efficacy in B-progenitor acute lymphoblastic leukemia (B-ALL). To determine tumor-intrinsic and -extrinsic determinants of response, we studied 44 adults with relapsed or refractory B-ALL (including 2 minimal residual disease positive) treated with blinatumomab using bulk tumor and single-cell sequencing. The overall response rate in patients with hematological disease was 55%, with a high response rate in those with CRLF2-rearranged Philadelphia chromosome-like ALL (12 [75%] of 16). Pretreatment samples of responders exhibited a tumor-intrinsic transcriptomic signature of heightened immune response. Multiple mechanisms resulted in loss of CD19 expression, including CD19 mutations, CD19-mutant allele-specific expression, low CD19 RNA expression, and mutations in CD19 signaling complex member CD81. Patients with low hypodiploid ALL were prone to CD19- relapse resulting from aneuploidy-mediated loss of the nonmutated CD19 allele. Increased expression of a CD19 isoform with intraexonic splicing of exon 2, CD19 ex2part, at baseline or during therapy was associated with treatment failure. These analyses demonstrate both tumor-intrinsic and -extrinsic factors influence blinatumomab response. We show that CD19 mutations are commonly detected in CD19- relapse during blinatumomab treatment. Identification of the CD19 ex2part splice variant represents a new biomarker predictive of blinatumomab therapy failure.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZQQ发布了新的文献求助10
刚刚
bkagyin的应助被科研通管家采纳,获得10
刚刚
1秒前
1秒前
aajhajkahna的应助被科研通管家采纳,获得10
1秒前
1秒前
xigualu发布了新的文献求助10
1秒前
demon1发布了新的文献求助10
1秒前
大个的应助被科研通管家采纳,获得10
1秒前
sendou的应助被科研通管家采纳,获得30
1秒前
游标卡尺发布了新的文献求助10
1秒前
111发布了新的文献求助10
1秒前
04d的应助被科研通管家采纳,获得20
1秒前
852的应助被科研通管家采纳,获得10
1秒前
vnewgnl的应助被科研通管家采纳,获得20
1秒前
benson完成签到,获得积分10
2秒前
2秒前
科目三的应助被speedness采纳,获得10
2秒前
大模型的应助被科研通管家采纳,获得30
2秒前
Faded发布了新的文献求助10
2秒前
xiepeijuan的应助被科研通管家采纳,获得10
2秒前
奔跑的应助被科研通管家采纳,获得10
2秒前
2秒前
汉堡包的应助被科研通管家采纳,获得10
2秒前
2秒前
aajhajkahna的应助被科研通管家采纳,获得10
3秒前
再见战王完成签到,获得积分10
3秒前
3秒前
3秒前
深情安青的应助被Lion采纳,获得10
3秒前
斯文败类的应助被顺意采纳,获得10
3秒前
4秒前
lilili的应助被坚定的平松采纳,获得10
4秒前
成就书芹发布了新的文献求助10
4秒前
李倩完成签到,获得积分10
4秒前
於煜城发布了新的文献求助10
4秒前
4秒前
芒果十六发布了新的文献求助10
5秒前
zmy发布了新的文献求助10
5秒前
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182977
求助须知:如何正确求助?哪些是违规求助? 9572322
关于积分的说明 21824168
捐赠科研通 7779612
什么是DOI,文献DOI怎么找? 3433774
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971